Current stock page

Financial Data

PFE Financial Data

Revenue · Earnings · Margins · Balance Sheet · Cash Flow

HealthcareDrug Manufacturers - GeneralScore data as of Oct 21, 2026

PFEPfizer Inc.

Healthcare / Drug Manufacturers - General

Relative Leader / Watch

Strong Relative Position

NeutralEdge 9/10
$29.85−$0.26 (−0.86%)

Latest quote

  • Momentum
    79
  • Value
    67
  • Quality
    54
  • Risk resilience
    54
  • Sentiment
    —
algovestiq.comScore data as of Oct 21, 2026

Financial Data Overview

Detailed revenue, earnings, margins, balance sheet, cash flow, valuation metrics, technical indicators, and risk measures for deeper research.

Quarterly periods
3
Fundamental metrics
10
Technical indicators
12
Risk measures
6

Quarterly Financial Statements

Updated Oct 21, 2026.

Income statement
3 periods
Metric2026-06-282026-03-292025-12-31
Revenue$15.03B$14.45B$17.56B
Gross Profit$10.94B$9.72B$12.29B
Operating Income$4.71B$4.03B$3.69B
Net Income-$246M$2.69B-$1.65B
EPS-$0.04$0.47-$0.29
Cash flow statement
3 periods
Metric2026-06-282026-03-292025-12-31
Operating Cash Flow$835M$2.62B$5.35B
Capital Expenditure-$533M-$436M-$845M
Free Cash Flow$302M$2.18B$4.5B
Net Cash Provided By Operating Activities$835M$2.62B$5.35B
Balance sheet
3 periods
Metric2026-06-282026-03-292025-12-31
Total Assets$201.13B$207.62B$0
Total Debt$63.42B$64.67B$72.58B
Cash And Cash Equivalents———
Total Liabilities$115.64B$117.21B-$93.1B
Total Stockholders Equity$85.49B$90.4B$93.1B
Key financial metrics
3 periods
Metric2026-06-282026-03-292025-12-31
P/E ratio-141.0314.77-21.47
P/B ratio1.631.751.64
P/S ratio9.2410.948.06
Debt To Equity0.740.720.78
Free Cash Flow Yield0.22%1.38%3.18%
Financial ratios
3 periods
Metric2026-06-282026-03-292025-12-31
P/E ratio-141.0314.77-21.47
P/B ratio1.631.751.64
P/S ratio9.2410.948.06
Return On Equity-0.29%2.98%-1.91%
Debt To Equity0.740.720.78

Current Stock Metrics

Current fundamental, technical, and risk readings in one place.

Fundamental metrics
MetricValue
Pe37.72x
Pb1.91x
Gross Margin71.32%
Operating Margin25.08%
ROE4.89%
ROIC9.33%
Debt To Equity0.74
FCF Yield6.75%

As of Oct 21, 2026

Technical indicators
MetricValue
Close$29.85
Volume22.14M
RSI (14)69.79
MACD0.51
MACD signal0.34
MACD histogram0.17
ADX (14)25.74
SMA (50)$28.15
SMA (200)$26.64
ATR (14)$0.55
Historical volatility (annualized)19.28%
Volume (20-day average)29.98M

As of Oct 21, 2026

Risk measures
MetricValue
Resilience score54/100
Beta0.28
Annual volatility21.51%
Max Drawdown-17.09%
Sharpe Ratio0.81
VaR (95%, 1-day)-2.02%

As of Oct 21, 2026

Detailed Metrics

Additional measures remain available here while the decision pages stay focused.

Additional fundamental metrics

No additional fundamental metrics are available.

Additional technical indicators

No additional technical indicators are available.

Additional risk measures

No additional risk measures are available.

PFE Financial Data FAQ

What is Pfizer Inc.'s revenue?

Pfizer Inc.'s revenue is one of the core financial data points for PFE. Use it with revenue growth, margins, and EPS to understand whether sales are translating into earnings power.

Is Pfizer Inc.'s revenue growing?

Revenue growth shows whether Pfizer Inc. is expanding from prior periods. Compare growth with margins and free cash flow because faster sales growth is more valuable when profitability holds up.

What is PFE's EPS?

PFE's EPS, or earnings per share, helps connect net income to each share. EPS should be compared with EPS growth, P/E ratio, and analyst expectations.

What is Pfizer Inc.'s net income?

Pfizer Inc.'s net income shows profit after costs, taxes, and other expenses. It should be read with revenue, operating margin, EPS, and free cash flow.

How much free cash flow does Pfizer Inc. generate?

Free cash flow shows how much cash Pfizer Inc. generates after capital spending. It is useful for judging reinvestment capacity, buybacks, debt reduction, and valuation support.

How much cash and debt does Pfizer Inc. have?

Cash and debt help frame PFE's balance-sheet flexibility. Compare liquidity and leverage with free cash flow and profitability before judging financial strength.